Memory processes are impacted by breathing patterns while you sleep.

Published Date: 20 Dec 2023

Researchers headed by Dr. Thomas Schreiner, head of the Emmy Noether junior research group at LMU's Department of Psychology, had previously demonstrated a direct correlation in 2021 regarding how memories are consolidated during sleep.

Read Full News

Latest News

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Insurance Formularies Holding Up Lower-Emission Asthma, COPD Inhalers

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

Why Doctors Need to Complete the COPD or Asthma Workup to Rule Out Alpha-1 Kyle Hogarth, MD

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

8 Pulmonology Headlines You Missed in September 2026

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

News All Time

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD Njira Lugogo, MD

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

Oral STAT6 Degraders Fill Niche in Asthma Care, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD Wim Wuyts, MD, PhD

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD Surya P. Bhatt, MD

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

STAT6 Degradation: A Novel Oral Target for Asthma? Victoria Johnson

At ERS 2026, pulmonologists framed oral STAT6 degradation—led by Kymera's KT-621—as a potential biologic-like, access-expanding approach.

ERS Congress 2026: 6 Late-Breaking Trials to Know Victoria Johnson

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Bridging the ROS1 Divide: Translating Biomarker Insights and Therapeutic Advances Into Community Oncology Practice for NSCLC

Bridging the ROS1 Divide: Translating Biomarker Insights and Therapeutic Advances Into Community Oncology Practice for NSCLC

Recommended News For You

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Race, Geography Linked to Gaps in Prostate Cancer Care

Novel probes to label macrophages associated with cancer progression using a selective dye

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Time to Rethink Maintenance Pemetrexed in NSCLC?

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Recommended Articles For You

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment 

Circulating Tumor DNA Dynamics for Therapy Matching: A Comprehensive Clinical Review 

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy 

Screening for Early Changes in Blood-Cell Production Capacity in Older Adults 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

AVD Chemo Regimen Shows Promise in Older Patients With HL

3.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

4.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

5.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

1.

Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations

2.

Contemporary Insights in Oncology in the Digital Era

3.

Strategic Concepts in Hematology for Modern Medicine

4.

Ferroptosis-Modulating Therapeutics in Precision Oncology

5.

Exploring the Potential of Bendamustine in Cancer Treatment

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

2.

Blood Clotting Disorders Explained

3.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

4.

Chemotherapy: What to Expect

5.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot